Nociceptin: brain peptide that shapes pain, stress, and mood (Orphanin FQ)
A natural brain chemical that activates its own dedicated pain and stress receptor, closely related to opioids but does not bind them; used as a lab research tool to study pain and reward circuits.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Nociceptin — also called Orphanin FQ (OFQ) — is a 17-amino-acid neuropeptide found in the brain. It looks structurally similar to the classical opioid peptides (like endorphins), and its very first residues even spell out the signature opioid motif, but it doesn't bind the classical mu, delta, or kappa opioid receptors. Instead it activates its own dedicated receptor, originally cloned as the "opioid receptor-like 1" receptor (ORL1, also called NOP). Researchers care about it because it sits at the boundary of the opioid system without being part of it, which makes it a useful tool for picking apart pain, stress, mood, and reward circuitry.
History
The ORL1 receptor was cloned in 1994 as an orphan member of the opioid receptor family — meaning the receptor was identified by sequence homology before anyone knew what activated it (Mollereau 1994, cited in cells9112400). The endogenous ligand was then identified independently by two groups in 1995: Meunier and colleagues named it nociceptin after observing that it lowered the pain threshold in mice (Nature 1995, cited in pnas.0805590105), while Reinscheid and colleagues named it Orphanin FQ — "FQ" for the N-terminal Phe and C-terminal Gln of the sequence — after isolating it as the ligand that activates the orphan receptor (Science 1995, cited in 2741/3306). Both names remain in use; the receptor is now most often called NOP.
What it does
In the brain, nociceptin modulates several behaviors that the classical opioid system also touches — but often in opposite directions. Jenck and colleagues (PNAS, 1997) showed that intracerebroventricular nociceptin acts as an anxiolytic in rodents, attenuating the behavioral inhibition that animals normally show under acutely stressful conditions, suggesting a role beyond pain in higher brain function. Other work in the dossier documents that nociceptin can functionally antagonize mu-, kappa-, and delta-opioid antinociception when given supraspinally (Mogil 1996, cited in sj.bjp.0704739) and that it reduces morphine-evoked dopamine release in the nucleus accumbens (Di Giannuario 1999, cited in fncel.2026.1774384). Because of these opposing actions, nociceptin has historically been described as an "anti-opioid" peptide, though that label oversimplifies a system that also modulates feeding, motor activity, and mood.
Mechanism
Nociceptin's selectivity for its own receptor — rather than for the classical opioid receptors it superficially resembles — is the point of interest for receptor pharmacologists. Adapa and colleagues (Neuropeptides, 1997) mapped the relationship between binding affinity and functional activity at the nociceptin/orphanin FQ receptor, the kind of structure-activity work needed to design selective NOP ligands. The receptor itself is a class A GPCR, and Mandyam and colleagues (2002, cited in fncel.2026.1774384) documented protein-kinase-C-dependent heterologous desensitization between NOP and the mu-opioid receptor, providing a molecular substrate for the cross-talk seen behaviorally. Stevens (Frontiers in Bioscience, 2009) places NOP and its ligand in the broader evolutionary tree of vertebrate opioid receptors, where the nociceptin/NOP pair appears to have diverged from the ancestral opioid system early enough that ligand selectivity was largely complete by the time the modern receptor subtypes settled out.
Evidence
- Human: No human clinical trial data on nociceptin itself is present in this dossier; the cited literature is preclinical and mechanistic.
- Animal: Anxiolytic-like effects on stress-induced behavioral inhibition in rodents (Jenck 1997). Supraspinal anti-opioid action on mu/kappa/delta antinociception (Mogil 1996). Reduction of morphine-induced nucleus accumbens dopamine release (Di Giannuario 1999). Modulation of feeding behavior (Pomonis 1996, cited in sj.bjp.0704739).
- In vitro: Binding-affinity / functional-activity profiling at the NOP receptor (Adapa 1997). PKC-mediated heterologous desensitization between NOP and mu-opioid receptors (Mandyam 2002).
Known effects
- Anti-opioid / opioid-modulating action — Preclinical, supraspinal site of action (Mogil 1996; Di Giannuario 1999)
- Anxiolytic-like behavior under acute stress — Preclinical (Jenck 1997)
- Feeding modulation — Preclinical (Pomonis 1996)
- Motor activity suppression along the mesoaccumbens axis — Preclinical (Narayanan 2004, cited in fncel.2026.1774384)
Related peptides
Nociceptin sits adjacent to, but outside of, the classical opioid peptide family. It belongs to the opioid-fold neuropeptide group by sequence and structure, while being pharmacologically distinct from the endorphins, enkephalins, and dynorphins that act on mu, delta, and kappa opioid receptors. Nocistatin — encoded by the same precursor gene as nociceptin — is a related peptide that often opposes nociceptin's actions on pain and feeding (Okuda-Ashitaka 2000, cited in neulet.2005.11.060).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the computer model be fooled into thinking nociceptin binds the mu-opioid receptor just because the two look alike on the surface?
If confirmed, this would protect drug developers from chasing the wrong biological target, saving years of misdirected research. It would also help scientists understand the limits of AI structure-prediction tools when peptides share only superficial similarity.
Could nociceptin reduce pain relief not by blocking opioid receptors directly, but by hushing the nerve cells that release the body's natural opioids?
If true, this could explain why stress sometimes worsens pain and could point toward new strategies for preserving natural painkiller activity in chronic pain patients, without the addiction risks of opioid drugs.
Could nociceptin reduce the runaway stress response seen in PTSD or anxiety disorders without the addiction risks of opioids or the sedation of tranquilizers?
If this works, it could offer a new class of treatment for people with PTSD or anxiety who do not respond to existing medications, potentially without the side effects that make current drugs hard to tolerate long-term.
Could nociceptin calm the stress signals that cause people to return to addictive drugs, while avoiding the pitfalls of opioid-based treatments?
If this holds, it could lead to new anti-relapse medications for opioid, alcohol, or stimulant addiction, especially for patients whose relapses are driven by stress, without creating a new dependency risk.
Could the cluster of positively charged building blocks in nociceptin's middle section be what steers it away from classical opioid receptors and toward its own dedicated receptor?
Understanding this could help chemists design shorter, cleaner drugs that hit only the nociceptin receptor, potentially treating pain or anxiety without the side effects tied to the classical opioid system.
Could swapping a single unit at the tip of nociceptin be enough to redirect it toward the classical opioid receptor that morphine targets?
If a single change controls which receptor a peptide targets, it could become a powerful design rule for building highly selective new drugs, potentially reducing the unwanted side effects that come from hitting the wrong receptor.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7351676821708679 | boltz-2 |
| ranking score | 0.7873250842094421 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.215 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10535,
sequence = {FGGFTGARKSARKLANQ},
target = {oprm1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}